Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03926169 · ClinicalTrials.gov registry record · Phase 2
A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
A Phase 2 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 243
- Enrollment target
NCT03926169 is a Phase 2 study that has completed, run by AbbVie. The registered enrollment target is 243 participants.
The verdict
NCT03926169, a Phase 2 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 243 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the safety and efficacy of risankizumab 180 mg and 360 mg versus placebo for the treatment of signs and symptoms of moderate to severe hidradenitis suppurativa (HS) in adult participants diagnosed for at least one year before the Baseline visit.
Interventions
- DRUG Risankizumab
- DRUG Placebo for risankizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2019-06-03 |
| Est. Completion | 2021-08-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03926169
The ClinicalTrials.gov registry entry for NCT03926169 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 243 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Risankizumab is the first listed.
NCT03926169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03926169 about?
NCT03926169 is a clinical study titled "A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa". The primary objective of this study is to assess the safety and efficacy of risankizumab 180 mg and 360 mg versus placebo for the treatment of signs and symptoms of moderate to severe hidradenitis suppurativa (HS) in adult participants diagnosed for at least one year before the Baseline visit.
What is the current status of trial NCT03926169?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 243 participants. The study started on 2019-06-03. Estimated completion is 2021-08-02.
What interventions are being tested in trial NCT03926169?
The interventions under investigation include: Risankizumab (DRUG), Placebo for risankizumab (DRUG).
Who is sponsoring clinical trial NCT03926169?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.